ABBV-932 clinical trials
Also written ABBV-932.
How each study uses ABBV-932 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ABBV-932 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ABBV-932
- 10
Studies by the year they started
10 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test ABBV-932.
- Nov 2026Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderPhase 2 · AbbVie
- Feb 2027A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar DisorderPhase 1 · AbbVie
- Mar 2027Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II DisorderPhase 2 · AbbVie
Studies
Open first, then newest update. How each study uses ABBV-932 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar DisorderRecruitingPhase 1AbbVieNCT07071532Written as ABBV-932
- Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderRecruitingPhase 2AbbVieNCT06846320Written as ABBV-932
- Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderCompletedPhase 2AbbVieNCT06605599Written as ABBV-932
- A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male ParticipantsCompletedPhase 1AbbVieNCT06953934Written as ABBV-932
- Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II DisorderActive, not recruitingPhase 2AbbVieNCT07220460Written as ABBV-932
- A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult ParticipantsCompletedPhase 1AbbVieNCT06849791Written as ABBV-932
- Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese ParticipantsCompletedPhase 1AbbVieNCT07024797Written as ABBV-932
- Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy VolunteersCompletedPhase 1AbbVieNCT06300580Written as ABBV-932
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)CompletedPhase 1AbbVieNCT06024239Written as ABBV-932
- Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult ParticipantsCompletedPhase 1AbbVieNCT05738850Written as ABBV-932